Journal:
:international journal of hematology-oncology and stem cell research
0
nasrin alizad ghandforoush msc, department of hematology, school of allied medical sciences, tehran university of medical sciences, tehran, iran
bahram chahardouli assistant professor, hematology-oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran
shahrbano rostami assistant professor, hematology-oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran
habibeh ghadimi msc student, hematology-oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran
ali ghasemi phd student of hematology, blood transfusion research center, high institute for research and education in transfusion medicine, tehran, iran
kamran alimoghaddam professor, hematology-oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran
background: minimal residual disease (mrd) tests provide early identification of hematologic relapse and timely management of acute myeloid leukemia (aml) patients. approximately, 50% of aml patients do not have clonal chromosomal aberrations and categorize as a cytogenetically normal acute myeloid leukemia (cn-aml). about 60% of adult cn-aml has a mutation in exon 12 of npm1 gene. this mutatio...